Menu
Golda Meir 7, Ness Ziona, Israel | Phone +972-8-9313433 | Fax: +972-8-9313434
Dr. Alon Seri-Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company that specialized in the development of peptide-based drug products.
Dr. Seri-Levy holds a Ph.D. in Chemistry (summa cum laude) from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following the pricing of our initial public offering.
Mr. Gilad Mamlok has served as our chief financial officer since February 2017.
From August 2015 to January 2017, Mr. Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv Stock Exchange, or TASE.
From September 2005 to March 2015, Mr. Mamlok served as senior vice president, global finance and accounting of Given Imaging Ltd., a medical device company dual listed on Nasdaq and TASE, acquired by Covidien plc in February 2014.
From January 2002 to September 2005, Mr. Mamlok served as chief financial officer of two other medical device companies.
Mr. Mamlok holds a Master’s degree in business economics from Tel-Aviv University and a B.A. in economics (magna cum laude) from Tel-Aviv University, Israel.
Dr. Ofer Toledano has served as our vice president of research and development since 2004.
Prior to joining Sol-Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Industries Ltd.), an Israeli manufacturer and distributor of crop protection products from 1998 until 2004.
Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.
Dr. Ofra Levy-Hacham has served as our vice president of clinical assurance and regulatory affairs since 2018, and as our vice president of quality and regulatory affairs from 2011 to 2018.
Prior to joining Sol-Gel, Dr. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a wholly owned subsidiary of Ferring Pharmaceuticals Ltd., and a fully integrated biopharmaceutical services private company from 2010 until 2011.
From 2005 until 2010, Dr. Levy-Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin disorders.
Dr. Levy-Hacham holds a Ph.D. in chemistry from The Technion – Israel Institute of Technology, Israel.
Mr. Nissim Bilman became Vice President Quality of Sol-Gel in August 2018.
Prior to joining Sol-Gel, Mr. Bilman served as CEO of QPRO Pharma, a project management and consulting company that offers services related to the pharmaceutical industry, from 2004 until 2018.
From 2011 to 2018, he served as VP Drug development of Exalenz Bioscience Ltd.
From 2007 until 2010, Mr. Bilman served as VP R&D and Manufacturing and Site Manager for Gelesis Inc./Gelesis R&D Ltd.
Mr. Bilman holds a Bachelor’s degree in Chemistry and Meteorology, as well as a Master of Science in Applied Chemistry, both from The Hebrew University, Jerusalem.
Dr. Karine Neimann has served as our vice president of projects and planning and chief chemist since September 2016.
Since joining us in 2008, Dr. Neimann held various positions, including as chief chemist and laboratory manager.
Dr. Neimann holds a Ph.D. in Chemistry from The Hebrew University of Jerusalem, Israel.
Dr. Itzik Yosef has served as our vice president of operations since August 2016.
Since joining us in 2010, Dr. Yosef held various positions including head of operations.
Dr. Yosef holds a Ph.D. in Chemistry from The Hebrew University of Jerusalem, Israel.
Dr. Dov Zamir has served as our vice president special projects since August 2016.
Prior to joining us, Dr. Zamir led the R&D group in CimaNanoTech Ltd., a private company developing sophisticated nanotechnology-based coating formulations from 2007 until 2016.
From 2004 to 2007, Dr. Zamir was VP of Pharma and Analytical R&D at Taro Pharmaceutical Industries in Haifa, and for three years prior to that he managed its Analytical R&D lab.
Dr. Zamir holds a Ph.D. in Organic Chemistry from Tel-Aviv University, Israel.
Prof. David Avnir is a Professor at the Institute of Chemistry, The Hebrew University of Jerusalem, where he received all his academic qualifications and where he held, among others, the positions of Head of the School of Chemistry, Head of the Institute of Chemistry and Head of the Graduate School in Experimental Sciences.
His current scientific activities include sol-gel organic hybrid materials and biomaterials, organically doped metals, and theoretical and experimental aspects of chirality and symmetry.
Prof. Avnir is one of Israel’s most cited chemists, and has received several awards including The Israel Chemical Society Prize (2011), placement on the Hebrew University’s “Wall of Innovators” (2012), and the Life Achievement Award of the International Sol-Gel Society (2013).
